U.S. Markets close in 5 hrs 48 mins

Gossamer Bio's stock falls 64% on findings for Phase 2 study for hypertension drug

Gossamer Bio's stock falls 64% on findings for Phase 2 study for hypertension drug

Shares of Gossamer Bio Inc. plunged 64.5% in premarket trading on Tuesday after Wall Street analysts questioned the performance of the company's experimental hypertension drug in a Phase 2 clinical trial. Though Gossamer said the drug, seralutinib, met the primary endpoint in a Phase 2 clinical trial, SVB Securities analyst Joseph Schwartz told investors that the therapy didn't outperform Merck & Co. Inc.'s sotatercept. "We expect the street to be disappointed in these topline results given both